Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | SQLE | Q14534 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5694030 | 1.00 | KDM1A (0.49) | KDM1APTPN1ALOX15MEN1CYP3A4 | |
| SCHEMBL18879119 | 0.84 | KDM1A (0.43) | KDM1APTPN1ALOX15MEN1CYP3A4 | |
| SCHEMBL21180974 | 0.83 | KDM1A (0.48) | KDM1APTPN1ALOX15MEN1CYP3A4 | |
| SCHEMBL28116876 | 0.79 | ALOX15 (0.36) | ALOX15SQLE | |
| SCHEMBL18879170 | 0.79 | KDM1A (0.44) | KDM1APTPN1ALOX15MEN1CYP3A4 | |
| SCHEMBL5693809 | 0.79 | ALOX15 (0.62) | KDM1APTPN1ALOX15MEN1CYP3A4 | |
| SCHEMBL5693810 | 0.79 | ALOX15 (0.62) | KDM1APTPN1ALOX15MEN1CYP3A4 | |
| SCHEMBL16464964 | 0.79 | ALOX15 (0.43) | ALOX15MEN1CYP3A4KMT2ASQLE | |
| SCHEMBL16464963 | 0.79 | ALOX15 (0.43) | ALOX15MEN1CYP3A4KMT2ASQLE | |
| SCHEMBL14030630 | 0.79 | ALOX15 (0.45) | KDM1AALOX15MEN1CYP3A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1110932-B1 | Process for the preparation of C10-C30-alkenes by partial hydrogenation of alkynes on fixed-bed palladium-supported catalysts | BASF AG (DE) | 2006-04-12 | — | — | EP | disclosed |
| US-6828468-B2 | By base-catalyzed monoethynylation of a ketone in liquid ammonia | BASF AKTIENGESELLSCHAFT (DE) | 2004-12-07 | — | — | US | disclosed |
| US-20020183565-A1 | Preparation of higher alpha, beta-unsaturated alcohols | BASF AKTIENGESELLSCHAFT (DE) | 2002-12-05 | — | — | US | disclosed |
| EP-1256560-A2 | Process for the preparation of higher alpha,beta-unsaturated alcohols | BASF AKTIENGESELLSCHAFT (DE) | 2002-11-13 | — | — | EP | disclosed |
| EP-1110932-A2 | Process for the preparation of C10-C30-alkenes by partial hydrogenation of alkynes on fixed-bed palladium-supported catalysts | BASF AKTIENGESELLSCHAFT (DE) | 2001-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183565-A1 | Preparation of higher alpha, beta-unsaturated alcohols | ADH1C, CHKB, PDK3 | KDM1A 2345/4885PTPN1 4644/4885ALOX15 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.